Skip to search formSkip to main content

AZD 8931

Known as: AZD-8931, AZD8931 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND A substantial change in trial methodology for solid tumours has taken place, in response to increased understanding of… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2016
2016
Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapies in the treatment of HER2-positive breast cancer… Expand
  • table 1
  • table 2
Is this relevant?
2016
2016
PurposeAZD8931 is an orally bioavailable, reversible tyrosine kinase inhibitor of EGFR, HER2, and HER3 signaling. The Phase II… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2015
2015
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signalling network is frequently de-regulated… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2014
Review
2014
HER2 (human epidermal growth factor receptor 2)-targeted therapy in breast cancer is one of the earliest and arguably most… Expand
Is this relevant?
2014
2014
Modest up-regulation of either HER-ligands or receptors has been implicated in acquired endocrine resistance. AZD8931, a dual… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
IntroductionEpidermal growth factor receptor (EGFR) overexpression has been associated with prognostic and predictive value in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
SummaryAim AZD8931 is an oral equipotent inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling. This Phase I, open… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2010
2010
PURPOSE To test the hypothesis that simultaneous, equipotent inhibition of epidermal growth factor receptor (EGFR; erbB1), erbB2… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?